Perinecrotic hypoxia contributes to ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases

American Journal of Pathology

Volumn 170, Issue 4, 2007, Pages 1379-1388

  Van Der Bilt, Jarmila D W ^a   Soeters, Marije E ^a   Duyverman, Annique M M J ^a   Nijkamp, Maarten W ^a   Witteveen, Petronella O ^a   Van Diest, Paul J ^a   Kranenburg, Onno ^a   Rinkes, Inne H M Borel ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Department of Surgery ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

17 DIMETHYLAMINOETHYLAMINO 17 DEMETHOXYGELDANAMYCIN; ARGININE; ATRASENTAN; HEAT SHOCK PROTEIN 90 INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; UNCLASSIFIED DRUG; 17 (DIMETHYLAMINOETHYLAMINO) 17 DEMETHOXYGELDANAMYCIN; 17-(DIMETHYLAMINOETHYLAMINO)-17-DEMETHOXYGELDANAMYCIN; BENZOQUINONE DERIVATIVE; HIF1A PROTEIN, MOUSE; MACROCYCLIC LACTAM; PYRROLIDINE DERIVATIVE;

ANIMAL MODEL; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MECHANISM; HYPOXEMIA; HYPOXIA; LIVER CELL DAMAGE; LIVER ISCHEMIA; MALE; MICROCIRCULATION; MICROMETASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; REPERFUSION; TISSUE NECROSIS; TUMOR GROWTH; ANIMAL; ANOXIA; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; COLORECTAL TUMOR; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; LIVER; LIVER TUMOR; METABOLISM; METASTASIS; NECROSIS; PATHOLOGY; PATHOPHYSIOLOGY; REPERFUSION INJURY; TIME; TUMOR CELL LINE; TUMOR VOLUME; VASCULARIZATION;

ANIMALS; ANOXIA; ARGININE; BENZOQUINONES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; LACTAMS, MACROCYCLIC; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICROCIRCULATION; NECROSIS; NEOPLASM TRANSPLANTATION; PYRROLIDINES; REPERFUSION INJURY; TIME FACTORS; TUMOR BURDEN;

EID: 34247842901     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2007.061028     Document Type: Article

References (76)

1. Scheele J, Altendorf-Hofmann A: Resection of colorectal liver metastases. Langenbecks Arch Surg 1999, 384:313-327
2. Malafosse R, Penna C, Sa Cunha A, Nordlinger B: Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol 2001, 12:887-894
3. Selzner M, Clavien PA: Resection of hepatic tumors: special emphasis on neoadjuvant and adjuvant therapy. Malignant Liver Tumors: Current and Emerging Therapies. Edited by PA Clavien. Sudbury, Jones and Bartlett Publishers, 2004, pp 153-169
4. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M: Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006, 94:982-999
5. Heisterkamp J, van Hillegersberg R, Ijzermans JN: Interstitial laser coagulation for hepatic tumours. Br J Surg 1999, 86:293-304
6. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004, 239:818-825
7. McKay A, Dixon E, Taylor M: Current role of radiofrequency ablation for the treatment of colorectal liver metastases. Br J Surg 2006, 93:1192-1201
8. Belghiti J, Marty J, Farges O: Techniques, hemodynamic monitoring, and indications for vascular clamping during liver resections. J Hepatobiliary Pancreat Surg 1998, 5:69-76
9. Dixon E, Vollmer CM, Bathe OF, Sutherland F: Vascular occlusion to decrease blood loss during hepatic resection. Am J Surg 2005, 190:75-86
10. Smyrniotis V, Farantos C, Kostopanagiotou G, Arkadopoulos N: Vascular control during hepatectomy: review of methods and results. World J Surg 2005, 29:1384-1396
11. Heisterkamp J, van Hillegersberg R, Mulder PG, Sinofsky EL, IJzermans JN: Importance of eliminating portal flow to produce large intrahepatic lesions with interstitial laser coagulation. Br J Surg 1997, 84:1245-1248
12. Patterson EJ, Scudamore CH, Owen DA, Nagy AG, Buczkowski AK: Radiofrequency ablation of porcine liver in vivo: effects of blood flow and treatment time on lesion size. Ann Surg 1998, 227:559-565
13. Carden DL, Granger DN: Pathophysiology of ischaemia-reperfusion injury. J Pathol 2000, 190:255-266
14. Jaeschke H: Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. Am J Physiol 2003, 284:G15-G26
15. Teoh NC, Farrell GC: Hepatic ischemia reperfusion injury: pathogenic mechanisms and basis for hepatoprotection. J Gastroenterol Hepatol 2003, 18:891-902
16. van der Bilt JD, Kranenburg O, Nijkamp MW, Smakman N, Veenendaal LM, te Velde EA, Voest EE, van Diest PJ, Borel Rinkes IHM: Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology 2005, 42:165-175
17. Koo A, Komatsu H, Tao G, Inoue M, Guth PH, Kaplowitz N: Contribution of no-reflow phenomenon to hepatic injury after ischemia-reperfusion: evidence for a role for superoxide anion. Hepatology 1992, 15:507-514
18. Pannen BH, Al Adili F, Bauer M, Clemens MG, Geiger KK: Role of endothelins and nitric oxide in hepatic reperfusion injury in the rat. Hepatology 1998, 27:755-764
19. Scommotau S, Uhlmann D, Loffler BM, Breu V, Spiegel HU: Involvement of endothelin/nitric oxide balance in hepatic ischemia/reperfusion injury. Langenbecks Arch Surg 1999, 384:65-70
20. Vollmar B, Glasz J, Leiderer R, Post S, Menger MD: Hepatic microcirculatory perfusion failure is a determinant of liver dysfunction in warm ischemia-reperfusion. Am J Pathol 1994, 145:1421-1431
21. Kondo T, Todoroki T, Hirano T, Schildberg FW, Messmer K: Impact of ischemia-reperfusion injury on dimensional changes of hepatic microvessels. Res Exp Med (Berl) 1998, 198:63-72
22. Martin C, Yu AY, Jiang BH, Davis L, Kimberly D, Hohimer AR, Semenza GL: Cardiac hypertrophy in chronically anemic fetal sheep: increased vascularization is associated with increased myocardial expression of vascular endothelial growth factor and hypoxia-inducible factor 1. Am J Obstet Gynecol 1998, 178:527-534
23. Tacchini L, Radice L, Bernelli-Zazzera A: Differential activation of some transcription factors during rat liver ischemia, reperfusion, and heat shock. J Cell Physiol 1999, 180:255-262
24. Marti HJ, Bernaudin M, Bellail A, Schoch H, Euler M, Petit E, Risau W: Hypoxia induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am J Pathol 2000, 156:965-976
25. Pichiule P, Agani F, Chavez JC, Xu K, LaManna JC: HIF-1 alpha and VEGF expression after transient global cerebral ischemia. Adv Exp Med Biol 2003, 530:611-617
26. Chi NC, Karliner JS: Molecular determinants of responses to myocardial ischemia/reperfusion injury: focus on hypoxia-inducible and heat shock factors. Cardiovasc Res 2004, 61:437-447
27. Lee JW, Bae SH, Jeong JW, Kim SH, Kim KW: Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol Med 2004, 36:1-12
28. Khan Z, Michalopoulos GK, Stolz DB: Peroxisomal localization of hypoxia inducible factors and hypoxia-inducible factor regulatory hydroxylases in primary rat hepatocytes exposed to hypoxia-reoxygenation. Am J Pathol 2006, 169:1251-1269
29. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E: Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998, 394:485-490
30. Giatromanolaki A, Harris AL: Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer. Anticancer Res 2001, 21:4317-4324
31. Pugh CW, Ratcliffe PJ: Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003, 9:677-684
32. Maxwell PH: The HIF pathway in cancer. Semin Cell Dev Biol 2005, 16:523-530
33. Brahimi-Horn C, Pouyssegur J: The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull Cancer 2006, 93:E73-E80
34. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM: Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha degradative pathway. J Biol Chem 2002, 277:29936-29944
35. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, Zhong H: Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002, 62:2478-2482
36. Zagzag D, Nomura M, Friedlander DR, Blanco CY, Gagner JP, Nomura N, Newcomb EW: Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion. J Cell Physiol 2003, 196:394-402
37. Alqawi O, Moghaddas M, Singh G: Effects of geldanamycin on HIF-1 alpha mediated angiogenesis and invasion in prostate cancer cells. Prostate Cancer Prostatic Dis 2006, 9:126-135
38. Drixler TA, Borel Rinkes IHM, Ritchie ED, van Vroonhoven TJ, Gebbink MF, Voest EE: Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res 2000, 60:1761-1765
39. te Velde EA, Vogten JM, Gebbink MF, Van Gorp JM, Voest EE, Borel Rinkes IHM: Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. Br J Surg 2002, 89:1302-1309
40. Vogten JM, Smakman N, Voest EE, Borel Rinkes IHM: Intravital analysis of microcirculation in the regenerating mouse liver. J Surg Res 2003, 113:264-269
41. Arteel GE, Thurman RG, Yates JM, Raleigh JA: Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br J Cancer 1995, 72:889-895
42. Samoszuk MK, Walter J, Mechetner E: Improved immunohistochemical method for detecting hypoxia gradients in mouse tissues and tumors. J Histochem Cytochem 2004, 52:837-839
43. Kietzmann T, Cornesse Y, Brechtel K, Modaressi S, Jungermann K: Perivenous expression of the mRNA of the three hypoxia-inducible factor alpha-subunits, HIF1alpha, HIF2alpha and HIF3alpha, in rat liver. Biochem J 2001, 354:531-537
44. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47
45. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996, 56:4509-4515
46. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999, 59:5830-5835
47. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL: The expression and distribution of the hypoxia-inducible factors HIF-1 alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000, 157:411-421
48. Bos R, Zhong H, Hanrahan CF, Mortimers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E: Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001, 93:309-314
49. van Diest PJ, Vleugel MM, van der Wall E: Expression of HIF-1alpha in human tumours. J Clin Pathol 2005, 58:335-336
50. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ: Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997, 94:8104-8109
51. Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, Bauer C, Gassmann M, Candinas D: HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 2001, 15:2445-2453
52. Bauer M, Zhang JX, Bauer I, Clemens MG: ET-1 induced alterations of hepatic microcirculation: sinusoidal and extrasinusoidal sites of action. Am J Physiol 1994, 267:G143-G149
53. Goto M, Takei Y, Kawano S, Nagano K, Tsuji S, Masuda E, Nishimura Y, Okumura S, Kashiwagi T, Fusamoto H: Endothelin-1 is involved in the pathogenesis of ischemia/reperfusion liver injury by hepatic microcirculatory disturbances. Hepatology 1994, 19:675-681
54. Marzi I, Takei Y, Rucker M, Kawano S, Fusamoto H, Walcher F, Kamada T: Endothelin-1 is involved in hepatic sinusoidal vasoconstriction after ischemia and reperfusion. Transpl Int 1994, 7(Suppl 1):S503-S506
55. Grant K, Loizidou M, Taylor I: Endothelin-1: a multifunctional molecule in cancer. Br J Cancer 2003, 88:163-166
56. Nelson J, Bagnato A, Battistini B, Nisen P: The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003, 3:110-116
57. Spinella F, Rosano L, Di Castro V, Natali PG, Bagnato A: Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1 alpha in ovarian carcinoma cells. J Biol Chem 2002, 277:27850-27855
58. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001, 357:539-545
59. Lewis CE, Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006, 66:605-612
60. Lin EY, Pollard JW: Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer 2004, 90:2053-2058
61. Ohno S, Suzuki N, Ohno Y, Inagawa H, Soma G, Inoue M: Tumor-associated macrophages: foe or accomplice of tumors? Anticancer Res 2003, 23:4395-4409
62. Tazawa H, Okada F, Kobayashi T, Tada M, Mori Y, Une Y, Sendo F, Kobayashi M, Hosokawa M: Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression. Am J Pathol 2003, 163:2221-2232
63. Lewis C, Murdoch C: Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol 2005, 167:627-635
64. Jaeschke H, Smith CW: Mechanisms of neutrophil-induced parenchymal cell injury. J Leukoc Biol 1997, 61:647-653
65. Chaudry IH: Cellular alterations in shock and ischemia and their correction. Physiologist 1985, 28:109-118
66. Lehnert M, Arteel GE, Smutney OM, Conzelmann LO, Zhong Z, Thurman RG, Lemasters JJ: Dependence of liver injury after hemorrhage/ resuscitation in mice on NADPH oxidase-derived superoxide. Shock 2003, 19:345-351
67. Höckel M, Dornhofer N: The hydra phenomenon of cancer: why tumors recur locally after microscopically complete resection. Cancer Res 2005, 65:2997-3002
68. Hofer SO, Molema G, Hermens RA, Wanebo HJ, Reichner JS, Hoekstra HJ: The effect of surgical wounding on tumour development. Eur J Surg Oncol 1999, 25:231-243
69. van der Bilt JD, Borel Rinkes IHM: Surgery and angiogenesis. Biochim Biophys Acta 2004, 1654:95-104
70. Clemens MG, Bauer M, Pannen BH, Bauer I, Zhang JX: Remodeling of hepatic microvascular responsiveness after ischemia/reperfusion. Shock 1997, 8:80-85
71. Peralta C, Rull R, Rimola A, Deulofeu R, Rosello-Catafau J, Gelpi E, Rodes J: Endogenous nitric oxide and exogenous nitric oxide supplementation in hepatic ischemia-reperfusion injury in the rat. Transplantation 2001, 71:529-536
72. Kuro T, Kohnou K, Kobayashi Y, Takaoka M, Opgenorth TJ, Wessale JL, Matsumura Y: Selective antagonism of the ETA receptor, but not the ETB receptor, is protective against ischemic acute renal failure in rats. Jpn J Pharmacol 2000, 82:307-316
73. Yamamoto S, Matsumoto N, Kanazawa M, Fujita M, Takaoka M, Gariepy CE, Yanagisawa M, Matsumura Y: Different contributions of endothelin-A and endothelin-B receptors in postischemic cardiac dysfunction and norepinephrine overflow in rat hearts. Circulation 2005, 111:302-309
74. Lo AC, Chen AY, Hung VK, Yaw LP, Fung MK, Ho MC, Tsang MC, Chung SS, Chung SK: Endothelin-1 overexpression leads to further water accumulation and brain edema after middle cerebral artery occlusion via aquaporin 4 expression in astrocytic end-feet. J Cereb Blood Flow Metab 2005, 25:998-1011
75. Melillo G: HIF-1: a target for cancer, ischemia and inflammation - too good to be true? Cell Cycle 2004, 3:154-155
76. Semenza GL: Development of novel therapeutic strategies that target HIF-1. Expert Opin Ther Targets 2006, 10:267-280